Thalidomide and dexamethasone: Therapy for multiple myeloma

Expert Review of Anticancer Therapy

Volumn 5, Issue 5, 2005, Pages 759-766

  Kumar, Shaji ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dexamethasone; Multiple myeloma; Thalidomide

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PREDNISONE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; VINCRISTINE; WARFARIN;

ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BALANCE DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; IMMUNOMODULATION; INFECTION; LUNG EMBOLISM; MICROENVIRONMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; SEDATION; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNCOPE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TREMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; RISK FACTORS; THALIDOMIDE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 27744566793     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.5.759     Document Type: Article

References (48)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335, 91-97 (1996).
4. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl. J. Med. 341, 1565-1571 (1999).
5. Rajkumar SV. Thalidomide: tragic past and promising future. Mayo. Clin. Proc. 79, 899-903 (2004).
6. Kumar S, Gertz MA, Dispenzieri A et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo. Clin. Proc. 78, 34-39 (2003).
7. Richardson P, Schlossman R, Jagannath S et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter Phase 2 study of efficacy, toxicity, and biological activity. Mayo. Clin. Proc. 79, 875-882 (2004).
8. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20, 4319-4323 (2002).
9. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21, 16-19 (2003).
10. Lenz W. Thalidomide and congenital abnormalities. Lancet 1, 45 (1962).
11. McBride WG. Thalidomide and congenital abnormalities. Lancet 2, 1358 (1961).
12. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085 (1994).
13. Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin. Pharmacol. Ther. 6, 298-302 (1965).
14. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin. Pharmacol. Ther. 6, 292-297 (1965).
15. Figg WD, Raje S, Bauer KS et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J. Pharm. Sci. 88, 121-125 (1999).
16. Piscitelli SC, Figg WD, Hahn B, Kelly G, Thomas S, Walker RE. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 41, 2797-2799 (1997).
17. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 57, 365-376 (2001).
18. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55, 1827-1834 (1998).
19. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. AntiCancer Drugs 7, 339-343 (1996).
20. Vacca A, Scavelli C, Montefusco V et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J. Clin. Oncol. 23, 5334-5346 (2005).
21. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680 (1993).
22. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 96, 2943-2950 (2000).
23. Niwayama S, Turk BE, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J. Med. Chem. 39, 3044-3045 (1996).
24. Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin. Oncol. 25, 53-57 (1998).
25. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr. Rev. 56, 35-39 (1985).
26. McHugh SM, Rifkin IR, Deighton J et al. The immunosuppressive drug thalidomide induces T-helper cell Type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 99, 160-167 (1995).
27. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem. 276, 22382-22387 (2001).
28. Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216 (2001).
29. Urashima M, Teoh G, Chauhan D et al. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 90, 279-289 (1997).
30. Chauhan D, Pandey P, Ogata A et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 15, 837-843 (1997).
31. Chauhan D, Pandey P, Hideshima T et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem. 275, 27845-27850 (2000).
32. Chauhan D, Auclair D, Robinson EK et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21, 1346-1358 (2002).
33. Barlogie B, Spencer T, Tricot G et al. Long-term follow-up of 169 patients receiving Phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). Blood 96, 514a (A2213) (2000).
34. Grosbois B, Bellissant E, Moreau P, Attal M, Zerbib R. Thalidomide (thal) in the treatment of advanced multiple myeloma (MM). a prospective study of 120 patients Blood 98 (2001) (Abstract 689).
35. Stewart KA, Chen C, Howson-Jan K et al. Results of a multi-center randomized Phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant. Blood 104 (2004) (Abstract 335).
36. Attal M, Harousseau JL, Leyvraz S et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the intergroupe francophone du myelome (IFM 99 02). Blood 104 (2004) (Abstract 535).
37. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med. 105, 8-11 (1986).
38. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80, 887-890 (1992).
39. Kumar S, Lacy MQ, Dispenzieri A et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 34, 485-490 (2004).
40. Rajkumar SV, Dingli D, Nowakowski G et al. Thalidomide and dexamethasone in newly diagnosed multiple myeloma: Long-term results in patients not undergoing upfront autologous stem cell transplantation. J. Clin. Oncol. (Meeting Abstracts) 23, 6632 (2005).
41. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106(1), 35-39 (2005).
42. Abdelkefi A, Torjman L, Ben Romdhane N et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 36(3), 193-198 (2005).
43. Rajkumar SV, Blood E, Vesole DH, Shepard R, Greipp PR. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a Phase III trial coordinated by the Eastern Co-operative Oncology Group. ASH Annual Meeting Abstracts 104, 205 (2004).
44. Barlogie B, Rasmussen E, Tricot G, Crowley J. Management of Patients with Multiple Myeloma (MM) Failing Total Therapy 2 (TT 2) According to Thalidomide (THAL) Randomization. ASH Annual Meeting Abstracts 104, 1483
45. Palumbo A, Giaccone L, Bertola A et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86(4), 399-403 (2001).
46. Palumbo A, Bertola A, Falco P et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J. 5, 318-324 (2004).
47. Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 12, 991-995 (2001).
48. Tosi P, Zamagni E, Cellini C et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur. J. Haematol. 73, 98-103 (2004).